• Can Acupuncture Help With Chemo Side Effects?

    John F. Sacco, MD, a board-certified radiation oncologist with OHC who is also board certified in Integrative and Holistic Medicine, and the National Cancer Institute, Blogs 0 comments
    November 21, 2018

    acupuncture and chemotherapy

    Although there is no evidence that acupuncture can help treat or cure cancer, research does suggest that it can help relieve some symptoms and side effects of treatment. Researchers propose that acupuncture stimulates the nervous system to release natural painkillers and immune system cells. They then travel to throughout the body and relieve symptoms. Acupuncture […]

    Read More
  • Protecting your skin is a year-round activity

    Comments from Suzanne Partridge, MD, medical oncologist and hematologist with OHC who serves as principal investigator for melanoma clinical trials research at OHC. Source: Dana-Farber/Brigham and Women’s Cancer Center for Skin Oncology, Blogs 0 comments
    November 19, 2018

    protecting your skin

    Just because the temperatures have dropped, it doesn’t mean we can forget about protecting our skin from the dangers associated with skin cancer. Ultraviolet rays can pass through those gray, overcast skies becoming especially dangerous for people heading to the ski slopes. Many “snowbirds” will head to a warmer climate and leave their sunscreen and […]

    Read More
  • Local Doctor Named Top “Real Man” in Cancer Fundraiser

    OHC, News Releases 0 comments
    November 16, 2018

    Real Men Wear Pink team

    FOR IMMEDIATE RELEASE November 16, 2018 Contact: Lesia Golden OHC Marketing Department 513-227-6771 Lesia.golden@usoncology.com OHC, the region’s premier source of treatment for nearly every form of adult cancer and complex blood disorder, is pleased to share that Joseph R. H. See, MD, a medical oncologist and hematologist at OHC Springfield and Dayton, was the top […]

    Read More
  • Targeted therapy allows doctors to more effectively treat cancer

    Kurt P. Leuenberger, MD, medical oncologist and hematologist at OHC, Blogs 0 comments
    November 15, 2018

    targeted therapy

    Targeted medicine, also known as personalized medicine, precision medicine, and genomic therapy, allows doctors to learn about a patient’s genetic makeup and how their tumor grows. They use this information to customize treatment specific to each patient’s condition. Before targeted medicine, most patients with a specific type and stage of cancer received the same treatment. […]

    Read More
  • What are Carcinoid Tumors and Should I be Concerned?

    Filix Kencana, MD, a medical oncologist and hematologist with OHC, Blogs 0 comments
    November 14, 2018

    what are carcinoid tumors

    November is Carcinoid Cancer Awareness Month and since not many people are aware of this condition, I’d like to answer some of the most commonly asked questions about this condition. What is carcinoid tumors/cancer? Carcinoid tumors (also called neuroendocrine tumors) are rare, slow-growing cancers that usually start in the lining of the digestive tract and […]

    Read More
  • Like Father, Like Daughter

    Lesia Golden, Patient Stories 0 comments
    November 12, 2018

    father and daughter OHC patient stories

    “I’ve always wanted to be like my dad,” said Jen Milau. One day, back in 2017, she learned that she was, in fact, just like her dad, Dan Prows. They were both diagnosed with lymphoma that same year, both had treatment-resistant conditions, and both would undergo stem cell transplants. Dan: I noticed a lump in […]

    Read More
  • Immunotherapy successful against deadly breast cancer

    Comments from Patrick Ward, MD, PhD, medical oncologist and co-director of research at OHC. Article by Maria Cohut, Medical News Today, Blogs 0 comments
    November 8, 2018

    triple negative breast cancer and immunotherapy

    A recent clinical trial could change the face of treatment for a very aggressive and stubborn form of breast cancer: triple-negative. Scientists found a combination of chemotherapy and immunotherapy boosts survival rates. Triple-negative breast cancer is so called since its cells lack receptors for two hormones (estrogen and progesterone) and one protein (HER2). In the […]

    Read More